Expanded Access for Rare Disease Treatment Announced
CANBERRA — Ultomiris has been added to the Pharmaceutical Benefits Scheme (PBS) for Australians suffering from generalised myasthenia gravis (gMG), as announced by the Minister for Health and Ageing, Mark Butler, at a World Rare Disease Day event. This inclusion is specifically for adults who are anti-acetylcholine receptor antibody positive, expanding treatment options for those affected by the debilitating condition.
The listing allows for patients with acute, severe gMG at high risk of rapid deterioration to access the treatment, as well as those requiring short-term disease control or who are unresponsive to other therapies. Susan White, Chairperson of Myasthenia Alliance Australia, expressed gratitude for this development, emphasizing the importance of accessible treatments for patients nationwide.
Understanding Generalised Myasthenia Gravis
GMG is a chronic autoimmune disorder leading to muscle weakness and fatigue. Symptoms can include slurred speech and difficulty swallowing, escalating to severe respiratory issues. Approximately 3,000 Australians live with gMG, with the majority being AChR Ab positive. Associate Professor Stephen Reddel highlighted the impact of gMG on daily life, noting the significance of having more treatment options available.
Nicole Gaupset, General Manager of Alexion Australasia, confirmed their commitment to supporting rare disease patients, acknowledging the long journey to this PBS listing. Healthcare professionals are advised to discuss treatment options with patients, considering potential side effects and the need for monitoring.
The inclusion of Ultomiris in the PBS is a significant step forward in healthcare for those with rare diseases. It not only provides financial relief for patients who require this treatment but also underscores the Australian government’s commitment to improving rare disease management. The availability of Ultomiris on the PBS is expected to enhance quality of life for many patients, offering them a chance to manage their symptoms more effectively and live with greater independence.
As awareness of gMG and similar conditions grows, the healthcare community in Australia continues to advocate for advancements in treatment and support systems. This move is seen as a critical development in the broader context of rare disease treatment, setting a precedent for future inclusions of essential medications in the PBS. Patients and healthcare providers alike are hopeful that such initiatives will lead to improved outcomes and a better understanding of rare conditions.
Source: newshub.medianet.com.au
Last updated: 1 April 2026, 10:33 am
